Figure 1.
Flowchart of participants in DEMAT study.
Table 1.
Differences in demography/reported history, baseline medical therapy, and clinical presentation in patients with suspected ACS, stratified by gender among DEMAT participants.
Figure 2.
Association between gender and in-hospital management (OR 95% CI), after adjustment for age, institution, education, history of smoking, diabetes, hypertension, hyperlipidemia; history of coronary heart disease, stroke, or heart failure; history of aspirin, clopidogrel, beta-blocker, statin, ACE inhibitor or ARB; presenting ST segment elevation myocardial infarction; and prior angiography.
Optimal care for in-hospital management includes administration of aspirin, clopidogrel, beta-blocker, statin, and unfractionated or low-molecular weight heparin. (UFH = unfractionated heparin; LMWH = low molecular weight heparin; GPIIb/IIIa = glycoprotein IIb/IIIa inhibitor; PCI = percutaneous coronary intervention; CABG = coronary artery bypass graft surgery).
Table 2.
Differences in in-hospital management and discharge management, stratified by gender among DEMAT participants.
Figure 3.
Association between gender and discharge medications (OR 95% CI), after adjustment for age, institution, education, history of smoking, diabetes, hypertension, hyperlipidemia; history of coronary heart disease, stroke, or heart failure; history of aspirin, clopidogrel, beta-blocker, statin, ACE inhibitor or ARB; presenting ST segment elevation myocardial infarction; and prior angiography.
Optimal care for discharge management includes administration of aspirin, clopidogrel, beta-blocker, and statin. (UFH = unfractionated heparin; LMWH = low molecular weight heparin; GPIIb/IIIa = glycoprotein IIb/IIIa inhibitor; PCI = percutaneous coronary intervention; CABG = coronary artery bypass graft surgery; ARB = angiotensin receptor blocker).
Table 3.
30-day outcomes among DEMAT participants, stratified by gender.
Table 4.
Association between gender and 30-day outcomes of DEMAT participants (reference: men).